Physician profile
Emily A Hoffmann
NPI 1477586345
$12,393.77
in general payments reported to CMS, 2019-2025
64 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,035 · 2022: $2,561 · 2023: $3,817 · 2024: $1,674 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,624 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,623.68 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,173.51 | 2023 | Cabometyx |
| Janssen Biotech, INC. | $1,139.92 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $973.15 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $781.70 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Seagen INC. | $711.74 | 2021-2023 | Tukysa, Padcev, Tivdak |
| Astellas Pharma US INC | $526.02 | 2021-2025 | Vyloy, Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $514.09 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $431.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $407.05 | 2021-2025 | Ninlaro, Iclusig |
| Novartis Pharmaceuticals Corporation | $402.49 | 2022-2025 | |
| Lilly USA, LLC | $391.42 | 2022-2025 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $371.79 | 2021-2025 | Trodelvy |
| Pfizer INC. | $359.29 | 2022-2025 | |
| Eisai INC. | $326.25 | 2021-2025 | |
| Celgene Corporation | $280.78 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $266.59 | 2021-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $261.85 | 2021-2025 | Brukinsa |
| Abbvie INC. | $255.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $166.27 | 2021-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $147.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $146.35 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $143.72 | 2021-2023 | Venclexta |
| Adaptive Biotechnologies Corporation | $135.36 | 2022-2025 | Clonoseq |
| Daiichi Sankyo INC. | $121.65 | 2021-2025 | Datroway, Enhertu |
| Taiho Oncology, INC. | $118.36 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $113.42 | 2022-2024 | Fotivda |
| Pharmacyclics LLC, An Abbvie Company | $92.95 | 2021-2022 | |
| Morphosys, US INC. | $88.60 | 2022-2023 | Monjuvi |
| Adc Therapeutics America, INC. | $84.74 | 2022-2023 | |
| G1 Therapeutics, INC. | $82.30 | 2022-2023 | Cosela |
| Sumitomo Pharma America, INC. | $78.45 | 2023 | Orgovyx |
| Tempus Ai, INC | $69.66 | 2024-2025 | Xt Cdx |
| Genmab U.S., INC. | $66.49 | 2023-2024 | Epkinly |
| Kyowa Kirin, INC. | $65.29 | 2021-2023 | Poteligeo |
| Puma Biotechnology, INC. | $60.66 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.69 | 2021-2025 | |
| Array Biopharma INC | $54.47 | 2021-2025 | Tukysa, Mektovi, Braftovi |
| Sobi, INC | $53.89 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $53.23 | 2025 | |
| Dova Pharmaceuticals | $51.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $51.27 | 2021-2023 | Xarelto |
| Incyte Corporation | $51.19 | 2021-2025 | Jakafi |
| Acrotech Biopharma INC. | $48.70 | 2021 | |
| Beone Medicines USA, INC. | $47.49 | 2025 | Brukinsa |
| Amag Pharmaceuticals, INC. | $44.77 | 2021 | |
| Pharmaessentia USA Corporation | $41.64 | 2023-2024 | Besremi |
| Emd Serono, INC. | $41.49 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $40.64 | 2025 | |
| Myovant Sciences INC. | $38.49 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $37.90 | 2023-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $36.28 | 2021-2022 | |
| Tersera Therapeutics LLC | $32.71 | 2024 | Zoladex |
| Pharmacosmos Therapeutics INC. | $29.76 | 2023-2024 | Cosela, Monoferric |
| Verastem, INC. | $26.78 | 2025 | Avmapki Fakzynja Co-Pack |
| Servier Pharmaceuticals LLC | $25.46 | 2021 | |
| Mirati Therapeutics, INC. | $23.30 | 2023 | Krazati |
| Recordati_rare_diseases_inc. | $22.67 | 2024 | Sylvant |
| Legend Biotech USA INC. | $22.59 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $20.10 | 2021 | |
| Acceleron Pharma, INC. | $18.63 | 2021 | |
| Spectrum Pharmaceuticals INC. | $16.76 | 2023 | Rolvedon |
| Corcept Therapeutics | $15.79 | 2025 | Korlym |
| Geron Corporation | $15.01 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $14.36 | 2023 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.